Stock Research Monitor: ACAD, AKAO, and AVDL
LONDON, UK / ACCESSWIRE / July 19, 2018 / If you want a free Stock Review on CDMO sign up now at www.wallstequities.com/registration. On Wednesday, July 18, 2018, US markets saw six out of nine sectors finishing the day in green, two in red, and one in neutral territory. Major US indices were also mixed at the close of yesterday’s session. The NASDAQ Composite ended the day at 7,854.44, down 0.01%; the Dow Jones Industrial Average edged 0.32% higher, to finish at 25,199.29; and the S&P 500 closed at 2,815.62, up 0.22%. This Thursday morning, WallStEquities.com looks at the performance of these four Biotechnology stocks: ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Achaogen Inc. (NASDAQ: AKAO), Avadel Pharmaceuticals PLC (NASDAQ: AVDL), and Avid Bioservices Inc. (NASDAQ: CDMO). All you have to do is sign up today for this free limited time offer by clicking the link below.
On Wednesday, shares in San Diego, California headquartered ACADIA Pharmaceuticals Inc. recorded a trading volume of 2.68 million shares. The stock ended the session 3.19% lower at $17.58. The Company’s shares have gained 11.05% in the last month. The stock is trading above its 50-day and moving average by 1.96%. Moreover, shares of ACADIA Pharma, which focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders, have a Relative Strength Index (RSI) of 53.89. Get the full research report on ACAD for free by clicking below at:
South San Francisco, California-based Achaogen Inc.’s stock closed the day 0.28% higher at $7.22 with a total trading volume of 808,930 shares. The stock is trading below its 50-day moving average by 34.89%. Additionally, shares of Achaogen, which focusses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant gram-negative infections in the US, have an RSI of 25.63. AKAO’s complimentary research coverage is a few simple steps away at:
Shares in Dublin, Ireland headquartered Avadel Pharmaceuticals PLC recorded a trading volume of 82,279 shares. The stock ended yesterday’s trading session 0.29% lower at $6.94. The stock is trading above its 50-day moving average by 1.37%. Furthermore, shares of Avadel Pharma, which develops and commercializes pharmaceutical products primarily for treating urology and sleep medicines in the US, France, and Ireland, have an RSI of 53.76. Register for your free research report on AVDL at:
Tustin, California-based Avid Bioservices Inc.’s stock finished Wednesday’s session 0.36% lower at $5.48 with a total trading volume of 1.29 million shares, which was above their three months average volume of 601.20 thousand shares. The Company’s shares have advanced 57.02% in the last month and 75.08% over the previous three months. The stock is trading above its 50-day and 200-day moving averages by 46.18% and 49.32%, respectively. Additionally, shares of Avid Bioservices, which operates as a contract development and manufacturing organization focusing on the development and cGMP manufacture of biopharmaceutical products derived from mammalian cell culture, have an RSI of 78.07. Wall St. Equities’ downloadable research report on CDMO available at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Wall St. Equities